Drugs For Hormonal Replacement Therapy Global Market Sees Growth Rate Of 8% Through 2022

The global drugs for hormonal replacement therapy market size is expected to grow from $11.13 billion in 2021 to $12.00 billion in 2022 at a compound annual growth rate (CAGR) of 7.8%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global hormonal replacement therapy market size is expected to reach $15.25 billion in 2026 at a CAGR of 6.2%.

What is the Global Drugs For Hormonal Replacement Therapy Market?

The drugs for hormonal replacement therapy market consists of sales of drugs for hormonal replacement therapy and related services. The drugs for hormonal replacement therapy are used to treat patients with growth hormone deficiency caused due to conditions such as dwarfism or menopause (a condition which describes changes a woman goes through when her menstruating cycle stops). The drugs for hormonal replacement therapy help to replace low level hormones from the body, maintain growth hormone deficiency and prevent women from vaginal dryness, mood swings, weakening of bones and others.

Get a Sample of the global drugs for hormonal replacement therapy market report
https://www.thebusinessresearchcompany.com/sample.aspx?id=2575&type=smp

What drives the Global Drugs For Hormonal Replacement Therapy Market?

Increasing population of aging and postmenopausal women is driving the drugs for hormonal replacement therapy market growth. Hormonal replacement therapy drugs such as Estrogen, Progestin and others are used to treat medical conditions caused due to menopausal conditions. According to a report by The Indian Menopause Society, New Delhi, in India there are 65 million women over the menopausal age affected with menopausal symptoms. According to European Menopause and Andropause Society (EMAS) report, women aged over 60 are expected to reach over 1 billion by 2050. In South Korea, the female population is expected to exceed male population by 2060, out of which 59.6% of female population is expected to suffer from postmenopausal symptoms. Thus, growing women population suffering from menopausal symptoms and aging population drives the market for hormonal replacement therapy drugs market.

Get the full global drugs for hormonal replacement therapy industry report here

Global Drugs For Hormonal Replacement Therapy Market Segments
The global drugs for hormonal replacement therapy market is segmented:
By Therapy Type: Estrogen Replacement Therapy, Human Growth Hormone (HGH) Replacement Therapy, Thyroid Replacement Therapy, Testosterone Replacement Therapy
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Application: Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, Menopause, Others
By Route of Administration: Oral, Parental, Others
By Geography: The regions covered in the drugs for hormonal replacement therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Drugs For Hormonal Replacement Therapy Global Market Report 2022 provides market size and growth forecasts for the global drugs for hormonal replacement therapy market, global drugs for hormonal replacement therapy market share, drugs for hormonal replacement therapy market segments and geographies, drugs for hormonal replacement therapy market competitive landscape including leading competitors’ revenues, profiles and market shares. The drugs for hormonal replacement therapy market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.

Global Drugs For Hormonal Replacement Therapy Industry Players include Novartis AG, Bayer AG, Pfizer Inc., Novo Nordisk A/S, Eli Lilly and Company, Abbott, Mylan Laboratories, Merck & Co, Hisamitsu Pharmaceutical Co Inc, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche, Noven Pharmaceuticals Inc., Orion Pharma AB, Allergan Plc, QuatRx Pharmaceuticals, Wyeth, Amgen Inc., Roche, Genentech and TherapeuticsMD. Based on industry trends and company analysis, the report explains a number of strategies for companies in the market.